Rare Neurological Disease (RND) Gene Panel

Genomic and Inherited Disorders

01-RND-27

NGS gene panel testing for Rare Neurological Diseases (Germline DNA) (including targeted panel testing/ virtual panel /clinical exome / WES / WGS)

Overview

The scheme

is designed to assess the entire diagnostic pipeline of a laboratory, including

sample receipt and processing, analytical processing (genotyping), and

reporting (biological and clinical interpretation of the test result) in the

context of a clinical referral, as well as reporting clarity, content and

clerical accuracy.

At a glance

Product Code:

01-RND-27

Target/Genes:

Panel testing of genes associated with rare neurological disease (RND). The scope of this EQA is broadly in line with the genes designated high evidence (green) on the Genomics England RND panel.

Technology:

CNV, MLPA, NGS, Panel testing, Whole exome sequencing, Whole genome sequencing

Sample Type:

DNA (in TE Buffer)

Submit Results In:

English, French, German, Italian, Spanish

Accredited:

Yes

Key Dates

Register by

30/11/2026

Samples ship

Jan-27

Survey Period

January - March 2027 (for exact dates, please see scheme instructions)

Final Results

August 2027

Sample Details

Three mock clinical cases, two with matching samples and one virtual case will be provided.

Approximately 2µg DNA per sample is provided. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

Testing can be performed using any appropriate panel for genes associated with rare neurological disease. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed.

This EQA is provided in collaboration with the European Reference Network for Rare Neurological Diseases (ERN-RND) – see website for more information.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

Send your enquiry by submitting the form

Closes in 21 days

From £467.00

Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.

Add to enquiry list
  • ISO 17043 accredited scheme
  • Submit results in 5 languages

Questions about this scheme?
Contact our team

Register Interest

Express your interest in ''.

Watch on YouTube (opens in a new tab)